Lithium manic-depressive psychosis

Nasrallah HA, Varney N, Coffman JA, et al Opiate antagonism fails to reverse post-ECT cognitive deficits. J Clin Psychiatry 47 555-556, 1986 Nasrallah HA, Coffman JA, Olson SC Structural brain-imaging findings in affective disorders an overview. J Neuropsychiatry Clin Neurosci 1 21-26, 1989 Naylor GJ, Smith AHW Defective genetic control of sodium-pump density in manic depressive psychosis. Psychol Med 11 257-263, 1981 Naylor GJ, McNamee HB, Moody JP Erythrocyte sodium and potassium in depressive illness. J Psychosom Res 14 173-177, 1970 Naylor GJ, McNamee HB, Moody JP Changes in erythrocyte sodium and potassium on recovery from depressive illness. Br J Psychiatry 118 219-223, 1971 Naylor GJ, Dick DAT, Dick EG, et al Lithium therapy and erythrocyte membrane cation carrier. Psychopharmacologia 37 81-86, 1974 Naylor GJ, Smith AHW, Dick EG, et al Erythrocyte membrane cation carrier in manic-depressive psychosis. Psychol Med 10 521-525, 1980... 

Baastrup PC. The use of lithium in manic-depressive psychosis. Compr Psychiatry 1964 5 396-408. 

Baastrup PC. Lithium-behandling of mani-depressiv psykose en psykoseforebyggende behandlingsmade (Lithium treatment of manic-depressive psychosis a procedure for preventing psychotic relapses). Nordisk Psykiatrisk Tiddskrift 1966 20 441-450. 

CONTROL OF MANIC EPISODES IN MANIC-DEPRESSIVE PSYCHOSIS USING LITHIUM... 

Baastrup, P. C. Schou, M. 1967, Lithium as a prophylactic agents. Its effect against recurrent depressions and manic-depressive psychosis, Arch.Gen. Psychiatry, vol. 16, no. 2, pp. 162-172. 

In 1949, Cade, in Australia, showed that lithium salts would control the manic phase of manic-depressive psychosis. This was the first effective psychotherapeutic agent of any kind, ante-dating even chlorpromazine. Possibly on account of the remoteness of his country. Cade s discovery was slow in gaining acceptance but is, today, the standard treatment (see further. Section 11.0). 

Lithium is important as the treatment of choice for manic depressive psychosis and this has provoked a wide variety of NMR studies in an endeavour to probe its mode of action. Organolithium compounds are used extensively in synthetic organic chemistry and as industrial catalysts, especially in polymerization reactions. 

Lenox RH, Manji HK Lithium, in The American Psychiatric Press Textbook of Psychopharmacology. Edited by Nemeroff C, Schatzberg A. Washington, DC, American Psychiatric Press, 1995, pp 303-349 Lenox RH, Watson DG Lithium and the brain a psychopharmacological strategy to a molecular basis for manic-depressive illness. Chn Chem 40(2 309-314, 1994 Lenox RH, Watson DG, Patel J, et al Chronic lithium administration alters a prominent PKC substrate in rat hippocampus. Brain Res 570 333-340, 1992 Lenzi A, Lazzerini F, Grossi E, et al Use of carbamazepine in acute psychosis a controlled study. J Int Med Res 14 78-84, 1986 Leonard BE Commentary on the mode of action of benzodiazepines. J Psychiatr Res 27 (suppl 1) 193, 1993... 

Despite this favorable result, lithium was hardly considered as a psychopharmaceutical for many years. There were a variety of reasons for this. Firstly, mania is not a very common psychosis and there is spontaneous remission in many cases. There were thus not so many occasions where lithium treatment was indicated. Secondly, lithium salts were considered to be toxic because for some time they had been given in excessive doses to patients with heart failure and in this way, had led to a number of fatalities (Cade, 1970). Thirdly, a few years after Cade s first publication psychiatrists attention had been claimed by chlorpromazine and the subsequent neuroleptics and antidepressants, thus explaining why lithium almost fell into oblivion. It was onl> in the 1960s that it once more attracted some interest, after the Danish psychiatrist Mogens Schou had shown that lithium salts were not only useful in the manic phase of manic depressive illness but also could prevent depressive episodes in patients suffering from bipolar psychoses. 

Because of concerns of the Food and Drug Administration, lithium vras removed Irom TUP during the early 1950s. At nearly the same time, psychiatrists discovered that the lithium ion has a remarkable therapeutic effect on the mental disorder called bipolar affective disorder, or manic-depressive iUiiess. Over 1 million Americans suffer horn this psychosis, undergoing severe mood swings from deep depression to a manic euphoria. The lithium ion smoothes these mood swin allowing the bipolar patient to function more effectively in daily life. 

It is well established that monotherapy with various antidepressants or mood stabilizers is relatively ineffective (i.e., they are necessary but not sufficient) for treating mood disorders with associated psychosis. Thus, psychotically depressed patients are best managed with a combination of antipsychotic-antidepressant or with electroconvulsive therapy. Although antipsychotics have a more rapid onset of action than lithium in an acute manic episode, we are unaware of clinical trials that examine the differential effect of antipsychotics or lithium for nonpsychotic versus psychotic mania. This topic is discussed further in... 

---